Anlon Healthcare Ltd

Anlon Healthcare Limited has responded to the stock exchange regarding a significant price movement in its securities. The company stated that it is unaware of any undisclosed information or events that could be influencing the price. Anlon Healthcare confirmed strict compliance with SEBI regulations, ensuring all material information is disclosed promptly. The company attributes the price fluctuation to market-driven factors, including general market conditions, investor sentiment, and trading activity, which are beyond its control. They have requested the exchange to take this clarification on record.

Anlon Healthcare Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, as required by SEBI regulations. The report, issued by CRISIL RATINGS LIMITED, covers the utilization of proceeds from its Initial Public Offer (IPO). The company reported no deviation in the utilization of funds against the objects stated in the prospectus, although a deviation was observed in the previous quarter (March 31, 2026) which was subsequently aligned with shareholder-approved changes to the objects. The net proceeds from the IPO amounted to ₹10,674.34 lakh.

Anlon Healthcare Ltd's Board of Directors met on August 13, 2026, approving audited standalone and consolidated financial statements for FY26. Key decisions include the appointment of directors, an internal auditor, and a significant increase in authorized share capital from ₹110 Cr to ₹130 Cr. The company also approved two share swap agreements to acquire up to 44.94% of Apiqo Organics Private Limited and up to 47.41% of Bizotic Lifescience Private Limited through preferential issuance of equity shares.

Anlon Healthcare Ltd's Board of Directors met on August 13, 2026, approving audited standalone and consolidated financial statements for FY26. Key decisions include the appointment of a director, regularization of an independent director, and appointment of an internal auditor. The company also approved a significant increase in authorized share capital from ₹110 Cr to ₹130 Cr, subject to shareholder approval. Furthermore, Anlon Healthcare will proceed with acquiring up to 44.94% of Apiqo Organics and 47.41% of Bizotic Lifescience through share swap agreements, involving the issuance of over 8.58 crore equity shares on a preferential basis.

Anlon Healthcare Ltd announced the outcome of its Board Meeting held on August 13, 2026. The board approved the audited standalone and consolidated financial statements for the Financial Year ended March 31, 2026. Key decisions also included the re-appointment of a director retiring by rotation, regularization of an independent director, appointment of an internal auditor for FY 2026-2027, and approval of the Cost Auditor's remuneration. Furthermore, the company approved an increase in authorized share capital from ₹110 Crore to ₹130 Crore, subject to shareholder approval. Significantly, Anlon Healthcare approved two share swap agreements to acquire up to 44.94% in Apiqo Organics Private Limited and up to 47.41% in Bizotic Lifescience Private Limited, involving the issuance of 8,58,83,617 equity shares on a preferential basis.

Anlon Healthcare Ltd has issued a revised intimation regarding its earlier disclosure on August 08, 2026. The company clarified that the percentage of acquisition in Apiqo Organics Private Limited (AOPL) was inadvertently stated as 32.52% instead of the correct 44.94%. Similarly, the acquisition percentage in Bizotic Lifescience Private Limited (BLPL) was revised from 43.33% to the correct 47.41%. The company regrets the error and confirms all other details from the previous intimation remain unchanged. The acquisition of AOPL is a related party transaction, undertaken on an arm's length basis, aimed at strengthening supply chains and enhancing shareholder value.

Anlon Healthcare Ltd has announced the postponement of its Board of Directors meeting, originally scheduled for August 11, 2026. The meeting has been rescheduled to August 13, 2026, due to administrative reasons. The agenda for the meeting remains unchanged. This update is in compliance with SEBI regulations.

Anlon Healthcare Limited has executed Share Swap Agreements (SSA) to acquire up to 32.52% stake in Apiqo Organics Private Limited (AOPL) and up to 43.33% stake in Bizotic Lifescience Private Limited (BLPL). The acquisitions will be made through the issuance of fresh equity shares on a preferential basis, without any cash consideration. AOPL is involved in manufacturing pharmaceutical intermediates and chemicals, with a turnover of ₹7,254.11 Lakh as of March 31, 2026. The acquisition aims to strengthen the supply of critical materials, achieve strategic synergies, and enhance shareholder value. The transactions are subject to necessary approvals and customary closing conditions, with completion expected within 90 days. The acquisitions are classified as related party transactions due to common promoters and directors but are conducted on an arm's length basis.

Anlon Healthcare Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from Thursday, August 06, 2026, and will remain in effect until 48 hours after the conclusion of the Board of Directors Meeting scheduled for Tuesday, August 11, 2026. The restriction applies to Promoters, Promoter group, Directors, Key Managerial Personnel, Designated Employees, Connected/Designated Persons, and their immediate relatives. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct, aimed at preventing insider trading and ensuring fair disclosure of unpublished price-sensitive information.

Anlon Healthcare Ltd has announced a Board of Directors meeting scheduled for August 11, 2026. The primary agenda items include the consideration and approval of audited standalone and consolidated financial statements for the fiscal year ending March 31, 2026. The board will also discuss several key strategic and operational matters such as director appointments, internal and cost auditor remuneration, enhancement of authorized share capital, alteration of the Memorandum of Association, borrowing powers, creation of security on company assets, and inter-corporate investments. A significant point of discussion will be the potential issuance of equity shares on a preferential basis for the acquisition of shares in Apiqo Organics Private Limited and Bizotic Lifescience Private Limited, along with related party transactions involving these entities and Remember India Health Links Private Limited. The meeting will also cover preparations for the Annual General Meeting, including fixing the date, venue, and approving the notice and appointment of scrutinizers.